Changeflow GovPing Healthcare & Life Sciences 2024 PMPRB Annual Report Shows $22.1B Patented ...
Routine Notice Added Final

2024 PMPRB Annual Report Shows $22.1B Patented Medicine Sales

Favicon for www.canada.ca PMPRB
Published
Detected
Email

Summary

The Patented Medicine Prices Review Board (PMPRB) has tabled its 2024 Annual Report in Parliament. The report documents $22.1 billion in sales of patented medicines in Canada for the reporting period. PMPRB continues its role as Canada's federal board responsible for reviewing patented medicine prices to ensure they are not excessive.

What changed

The Patented Medicine Prices Review Board released its 2024 Annual Report documenting $22.1 billion in patented medicine sales in Canada. The report provides transparency on the pharmaceutical market and PMPRB's regulatory oversight activities for the year.

For pharmaceutical companies and stakeholders, this report offers insights into market trends and pricing patterns in Canada's patented medicine sector. The document is informational and does not create new compliance obligations. Affected parties should review the full report for detailed market data and PMPRB findings.

What to do next

  1. Monitor for additional PMPRB updates and reports

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Get daily alerts for PMPRB

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from PMPRB.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
PMPRB
Published
December 3rd, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Government agencies Public health authorities
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug pricing monitoring Annual reporting Regulatory oversight
Geographic scope
Canada CA

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Topics
Healthcare Consumer Finance

Get alerts for this source

We'll email you when PMPRB publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!